History and development of continuous renal replacement techniques.

Kidney international. Supplement Pub Date : 1998-05-01
H Burchardi
{"title":"History and development of continuous renal replacement techniques.","authors":"H Burchardi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In 1966 two research groups, one in the United States and the other in Germany, were independently evaluating new membranes for renal replacement techniques. These filters were characterized by high filtration rates, where solutes up to a certain molecular weight were filtered by convection. At the same time the understanding of the transport mechanisms through membranes was improving. In 1976 Burton created the term \"hemofiltration\" for this new convective technique, and the first multicenter trial was initiated to evaluate its effectiveness for treating chronic renal failure. In 1977 Kramer in Göttingen (Germany) developed the continuous arteriovenous hemofiltration (CAVH) technique, which used a systemic arteriovenous pressure difference in an extracorporeal circuit to continuously produce an ultrafiltrate. The advantages of this effective method for elimination of fluid and solutes were its technical simplicity and the hemodynamic stability of even critically ill patients. Therefore, it soon became a widely used method for treating acute renal failure in intensive care patients. However, its limited capacity to remove nephrotoxins in the presence of high catabolism and complications connected to the arterial access lead to the development of a venovenous pump-driven technique (CVVH) in order to become independent from the systemic circulation and the arterial access. Further progress to improve solute clearance was made by combining the convective principle of hemofiltration with the diffusive transport of dialysis (continuous arteriovenous hemodialysis or hemodiafiltration). Today this combination has become the most effective renal replacement technique for treating acute renal failure in critically ill patients.</p>","PeriodicalId":17704,"journal":{"name":"Kidney international. Supplement","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1998-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney international. Supplement","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In 1966 two research groups, one in the United States and the other in Germany, were independently evaluating new membranes for renal replacement techniques. These filters were characterized by high filtration rates, where solutes up to a certain molecular weight were filtered by convection. At the same time the understanding of the transport mechanisms through membranes was improving. In 1976 Burton created the term "hemofiltration" for this new convective technique, and the first multicenter trial was initiated to evaluate its effectiveness for treating chronic renal failure. In 1977 Kramer in Göttingen (Germany) developed the continuous arteriovenous hemofiltration (CAVH) technique, which used a systemic arteriovenous pressure difference in an extracorporeal circuit to continuously produce an ultrafiltrate. The advantages of this effective method for elimination of fluid and solutes were its technical simplicity and the hemodynamic stability of even critically ill patients. Therefore, it soon became a widely used method for treating acute renal failure in intensive care patients. However, its limited capacity to remove nephrotoxins in the presence of high catabolism and complications connected to the arterial access lead to the development of a venovenous pump-driven technique (CVVH) in order to become independent from the systemic circulation and the arterial access. Further progress to improve solute clearance was made by combining the convective principle of hemofiltration with the diffusive transport of dialysis (continuous arteriovenous hemodialysis or hemodiafiltration). Today this combination has become the most effective renal replacement technique for treating acute renal failure in critically ill patients.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
连续肾替代技术的历史和发展。
1966年,两个研究小组,一个在美国,另一个在德国,独立地评估用于肾脏替代技术的新膜。这些过滤器的特点是高过滤速率,其中溶质达到一定分子量通过对流过滤。与此同时,对膜转运机制的认识也在不断提高。1976年,Burton为这种新的对流技术创造了“血液滤过”一词,并开始了第一个多中心试验,以评估其治疗慢性肾衰竭的有效性。1977年,Göttingen(德国)的Kramer开发了连续动静脉血液滤过(CAVH)技术,该技术在体外回路中利用全身动静脉压差连续产生超滤液。这种消除液体和溶质的有效方法的优点是技术简单,甚至对危重病人的血流动力学稳定。因此,它很快成为治疗重症患者急性肾功能衰竭的一种广泛使用的方法。然而,在存在高分解代谢和与动脉通路相关的并发症的情况下,其去除肾毒素的能力有限,这导致了静脉-静脉泵驱动技术(CVVH)的发展,以便独立于体循环和动脉通路。将血液滤过的对流原理与透析的弥漫性转运(持续动静脉血液透析或血液滤过)相结合,在提高溶质清除率方面取得了进一步进展。今天,这一组合已成为治疗危重病人急性肾功能衰竭最有效的肾脏替代技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Alport syndrome. New strategies to prevent cardiovascular risk in chronic kidney disease. Proceedings of the Sixth International Conference on Hypertension and the Kidney. February 2008. Madrid, Spain. Prevention of Renal Disease in the Emerging World: Toward Global Health Equity. Proceedings of the Bellagio Conference, March 16-18, 2004, Italy. The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid. Proceedings of the Third International Conference on Hypertension and the Kidney, February 2002, Madrid, Spain.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1